BridgeBio Pharma (BBIO) Gains 7.46% for June 23

Equities Staff  |

Shares of BridgeBio Pharma Inc (NASDAQ:BBIO) moved 7.46% higher on June 23 to close at $9.08.

2,264,881 exchanged hands. Their current average 30 day volume is 2,139,839 shares.

BridgeBio Pharma has moved 49.34% year-to-date in 2022.

The company is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on BridgeBio Pharma visit the company profile.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

To get more information on BridgeBio Pharma Inc and to follow the company's latest updates, you can visit the company's profile page here: BridgeBio Pharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content